- Home
- DUO vs NRSN Comparison
DUO vs NRSN Comparison
Compare DUO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUO
- NRSN
- Stock Information
- Founded
- DUO 2011
- NRSN 2017
- Country
- DUO China
- NRSN Israel
- Employees
- DUO N/A
- NRSN N/A
- Industry
- DUO Real Estate
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- DUO Finance
- NRSN Health Care
- Exchange
- DUO Nasdaq
- NRSN Nasdaq
- Market Cap
- DUO 17.1M
- NRSN 17.8M
- IPO Year
- DUO 2019
- NRSN 2021
- Fundamental
- Price
- DUO $0.58
- NRSN $1.09
- Analyst Decision
- DUO
- NRSN Hold
- Analyst Count
- DUO 0
- NRSN 1
- Target Price
- DUO N/A
- NRSN N/A
- AVG Volume (30 Days)
- DUO 4.3M
- NRSN 159.3K
- Earning Date
- DUO 04-17-2025
- NRSN 04-04-2025
- Dividend Yield
- DUO N/A
- NRSN N/A
- EPS Growth
- DUO N/A
- NRSN N/A
- EPS
- DUO N/A
- NRSN N/A
- Revenue
- DUO $37,352,654.00
- NRSN N/A
- Revenue This Year
- DUO N/A
- NRSN N/A
- Revenue Next Year
- DUO N/A
- NRSN N/A
- P/E Ratio
- DUO N/A
- NRSN N/A
- Revenue Growth
- DUO 6.61
- NRSN N/A
- 52 Week Low
- DUO $0.32
- NRSN $0.51
- 52 Week High
- DUO $4.67
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- DUO 46.49
- NRSN 44.12
- Support Level
- DUO $0.57
- NRSN $1.12
- Resistance Level
- DUO $0.67
- NRSN $1.24
- Average True Range (ATR)
- DUO 0.04
- NRSN 0.08
- MACD
- DUO 0.00
- NRSN -0.01
- Stochastic Oscillator
- DUO 12.40
- NRSN 13.57
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. Through its subsidiaries, It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.